Trigeminal Nerve Stimulation for Depression: Dose Finding

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Ian A. Cook, M.D., University of California, Los Angeles
ClinicalTrials.gov Identifier:
NCT01343563
First received: April 5, 2011
Last updated: February 4, 2013
Last verified: February 2013
  Purpose

This study will aim to examine the use of external trigeminal nerve stimulation (TNS) as an adjunctive treatment for adults with major depressive disorder (MDD) when added onto antidepressant medications. Our primary objective is the examination of two different "doses" of TNS, in terms of pulse frequency.

To accomplish our specific aims, the investigators will test the following specific hypotheses:

  1. Subjects will show greater improvement in ratings of mood and other symptoms of depression during the six-week of high frequency stimulation than during low frequency stimulation periods.
  2. Subjects will show greater improvement after 12 weeks of high frequency stimulation than after six weeks of high frequency stimulation.
  3. Subjects will show improvement in ratings of life functional capacity and quality of life with TNS.
  4. Subjects will report the TNS treatments to be acceptable in terms of side effects and burden of using the device.
  5. Subjects will show significant differences in regional brain function at the end of the high frequency stimulation period compared with baseline, and significant differences between high and low frequency stimulation conditions.

Condition Intervention Phase
Depression
Procedure: Trigeminal Nerve Stimulation
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Official Title: Trigeminal Nerve Stimulation for Depression: Dose Finding

Resource links provided by NLM:


Further study details as provided by University of California, Los Angeles:

Primary Outcome Measures:
  • Change in Hamilton Depression Rating Scale 17 score [ Time Frame: baseline, week 6, week 12 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Change in life functional capacity and quality of life scales [ Time Frame: baseline, week 6, week 12 ] [ Designated as safety issue: No ]
    Life functional capacity and quality of life scales include: Short-form Health Survey-36 Item and Quality of Life Enjoyment and Satisfaction Questionnaire

  • Changes in Regional Brain Function [ Time Frame: baseline, week 6, week 12 ] [ Designated as safety issue: No ]
    As measured by qualitative electroencephalographic (QEEG) recordings

  • Changes in vital signs recordings [ Time Frame: At every visit for 12 weeks ] [ Designated as safety issue: Yes ]
    Autonomic function (i.e. pulse and blood pressure) are monitored for 30 mins of stimulation at baseline, week 6, and week 12. Resting vital signs are recorded for each visit.

  • Changes in Safety Assessment Measures [ Time Frame: At every visit for 12 weeks ] [ Designated as safety issue: Yes ]
    Safety Assessment measures will be administered at each visit and include: Survey of Acceptability of TNS, Systematic Assessment for Treatment Emergent Events-Systematic Inquiry (SAFTEE-SI), and Frequency, Intensity, and Burden of Side Effects Scale (FIBSER)


Enrollment: 20
Study Start Date: January 2011
Study Completion Date: January 2012
Primary Completion Date: January 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Low frequency to High
For the first six weeks, subjects randomized to this group will receive low frequency stimulation. At the six week point, the low frequency group subjects will be crossed over to high frequency for the remaining six weeks.
Procedure: Trigeminal Nerve Stimulation
External trigeminal nerve stimulation (TNS) as an adjunctive treatment added onto antidepressant medications.
Active Comparator: High frequency
Subjects randomized to this group will receive high frequency stimulation for the entire 12 weeks of the first phase of this study.
Procedure: Trigeminal Nerve Stimulation
External trigeminal nerve stimulation (TNS) as an adjunctive treatment added onto antidepressant medications.

Detailed Description:

A total of 20 subjects with Major Depressive Disorder (MDD), ages 18 to 65, will be consented and join this project at UCLA.

The project has two phases: a 12 week treatment phase and a 6 month follow-up phase. In the first phase, a double-blind one-way cross-over design will allow us to compare the clinical and physiologic responses to TNS at two frequencies of stimulation, "high" (~120 Hz) and "low " (~20 Hz). Subjects will be randomized to start a six week period at either high or low frequency stimulation (n=10 in each); both subjects and the staff who interact with them will be blinded to assignment, and a separate member of the team will program the device settings. At the six week point, the low frequency group subjects will be crossed over to high frequency, while the high frequency group will continue at high frequency. At the end of the 12 weeks, the TNS systems will be returned and the adjunctive treatment will end. All subjects will be followed for another six months with monthly telephone calls to monitor symptoms or changes in treatment that would signal a return of symptoms. The primary endpoint is the change in depression severity for the two groups at the week 6 visit.

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria

  1. Outpatients with non-psychotic, unipolar Major Depressive Disorder assessed via the MINI structured interview
  2. A score of ≥ 14 on the HAM-D17 with Item 1 (depressed mood) ≥ 2
  3. A history of treatment failure with at least one adequate trial of an antidepressant over the previous 6 weeks, with no change in antidepressant medication or dose within the previous 6 weeks, and ongoing use of at least one antidepressant (which will continue during participation in the study)
  4. Age range: 18 to 65 years old.
  5. Patients with suicidal ideation are eligible only if the thoughts of death or of life not being worth living are not accompanied by a plan or intention for self-harm.

Exclusion Criteria

  1. Patient is mentally or legally incapacitated, unable to give informed consent.
  2. Patients with psychosis (psychotic depression, schizophrenia, or schizoaffective diagnoses (lifetime)); bipolar disorder (lifetime); dementia (lifetime); delirium or any substance abuse disorder within the past 6 months; eating disorder within the past year; obsessive-compulsive disorder (lifetime); post-traumatic stress disorder within the past year; acute risk for suicide or self-injurious behavior. Patients with diagnostic uncertainty or ambiguity (e.g. rule-out pseudodementia of depression) will be excluded.
  3. Patients with exposure to ECT or VNS within the past 6 months.
  4. Past history of skull fracture; cranial surgery entering the calvarium; space occupying intracranial lesion; stroke, CVA, or TIAs; cerebral aneurysm; Parkinson's or Huntington's disease; or Multiple Sclerosis.
  5. current pregnancy, breast feeding, plans to become pregnant in the 12-week treatment phase of the study, or not using a medically accepted means of contraception.
  6. Other medical contraindications to any of the study procedures
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01343563

Locations
United States, California
Semel Institute for Neuroscience and Human Behavior at UCLA
Los Angeles, California, United States, 90024
Sponsors and Collaborators
University of California, Los Angeles
Investigators
Principal Investigator: Ian A Cook, MD Semel Institute for Neuroscience and Human Behavior
  More Information

No publications provided

Responsible Party: Ian A. Cook, M.D., Principal Investigator, University of California, Los Angeles
ClinicalTrials.gov Identifier: NCT01343563     History of Changes
Other Study ID Numbers: 10-000480, 10-000480
Study First Received: April 5, 2011
Last Updated: February 4, 2013
Health Authority: United States: Institutional Review Board

Keywords provided by University of California, Los Angeles:
Depression
Major Depressive Disorder (MDD)
EEG
Trigeminal Nerve Stimulation

Additional relevant MeSH terms:
Depression
Depressive Disorder
Behavioral Symptoms
Mood Disorders
Mental Disorders

ClinicalTrials.gov processed this record on July 20, 2014